A photo of Rhonda Szczesniak.

Associate Professor, UC Department of PediatricsUC Department of Environmental Health; UC Department of Mathematical Sciences


Biography & Affiliation


Dr. Szczesniak's research program in cystic fibrosis computational medicine is emerging through a strong partnership with the Cystic Fibrosis Foundation and support from NIH. She has standing reviewer positions on grant award panels and is a member of the Cystic Fibrosis Foundation Patient Registry/Comparative Effectiveness Research Committee. She currently leads an initiative with an international consortium of MD/PhD researchers and clinicians on identifying the best practices for the analysis of lung function decline. She currently has an award to sponsor another faculty biostatistician for a career in CF comparative effectiveness research with translation of model systems based on the Cystic Fibrosis Foundation Patient Registry. Her published work leading up to this award was featured on the cover and in an editorial from the Annals of the American Thoracic Society. Most recently, her work on phenotypes of rapid cystic fibrosis lung disease was published in the American Journal of Respiratory and Critical Care Medicine and was highlighted in an accompanying editorial.

Clinical Interests

Cystic fibrosis; blood pressure; glycemic control

Research Interests

Functional data analysis; longitudinal data analysis; medical monitoring; prediction

Academic Affiliation

Associate Professor, UC Department of PediatricsUC Department of Environmental Health; UC Department of Mathematical Sciences




PhD: Statistics, University of Kentucky, Lexington, KY, 2007.

MS: Statistics, University of Kentucky, Lexington, KY, 2005.

BS: Mathematics, Radford University, Radford, VA, 2003.


Szczesniak R, Li D, Su W, Brokamp C, Pestian J, Seid M, Clancy JP. Phenotypes of Rapid Cystic Fibrosis Lung Disease Progression during Adolescence and Young Adulthood. Am J Respir Crit Care Med. 2017;196(4):471-478.

Szczesniak R, Heltshe S, Stanojevic S, Mayer-Hamblett N. Use of FEV1 in Cystic Fibrosis Epidemiologic Studies and Clinical Trials: A Statistical Perspective for the Clinical Researcher. J Cyst Fibros. 2017;16(3):318-26.

Szczesniak R, Li D, Duan LL, Altaye M, Miodovnik M, Khoury JC. Longitudinal Patterns of Blood Pressure, Insulin and Glucose Control during Type I Diabetic Pregnancy: Phenotypes from Functional Data Analysis. Am J Perinatol. 2016;33(13):1282-1290. 

Szczesniak R, Li D, Amin R. Semiparametric mixed models for nested repeated measures applied to ambulatory blood pressure monitoring data. J Mod Appl Stat Methods. 2016;15(1):255-275. 

Heltshe S, Szczesniak R. FEV1 variability in CF- has the clinical utility been lost in statistical translation? J Pediatr. 2016. 

Szczesniak R, McPhail GL, Li D, Amin R, Clancy JP. Predicting Future Lung Function Decline in Cystic Fibrosis Patients: Statistical Methods and Clinical Connections. Pediatr Pulmonol. 2016;51(2):217-8.

Szczesniak R, McPhail G, Duan L, Li D, Macaluso M, Amin R, Clancy JP. A Semiparametric Approach to Estimate Rapid Lung Function Decline in Cystic Fibrosis. Ann Epidemiol. 2013;23(12):771-7.

Cudzilo C*, Szczesniak R*, Brody AS, Rattan M, Krueger DA, Bissler JJ, Franz DN, McCormack FX, Young LR. Lymphangioleiomyomatosis Screening in Women with Tuberous Sclerosis. Chest. 2013;144(2):578-85. *authors contributed equally to this work.

VanDyke R, McPhail G, Huang B, Fenchel M, Amin R, Carle A, Chini B, Seid M. Tobramycin is effective in slowing lung function decline in cystic fibrosis: an instrumental variables analysis. Ann Am Thorac Soc. 2013;10(3):205-12.

Young LR, VanDyke R, Gulleman P, Yoshikazu I, Brown KK, Schmidt L, Hajjar F, Trapnell B, Franz D, McCormack F. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest. 2010;138(3):674-681.